Unlock New Insights with Selective Measurement of BD-Tau

Flyer

Brain-derived tau (BD-Tau) is enhancing our understanding of neurodegenerative diseases. As an emerging bloodbased biomarker, BD-Tau is demonstrating potential in distinguishing Alzheimer’s disease (AD) from other neurodegenerative conditions, predicting cognitive decline in AD subgroups, and assessing severe traumatic brain injury (sTBI). The Simoa® BD-Tau Advantage PLUS assay (104797) provides ultra-sensitive and selective measurement of BD-Tau proteins in biological samples. This assay offers new insights to advance research into AD and other neurological conditions. Download our flyer to learn more.

If you see this, do not fill:

Fill in the form below.

First Name *
Last Name *
Email *
Company *
What type of organization is your company? *
Country *
State *
Postal Code *
What therapeutic area(s) are of interest?
To select multiple values, hold down the Shift or Control (PC) or Command (Mac) key.
What product(s) are you interested in? *
To select multiple values, hold down the Shift or Control (PC) or Command (Mac) key.
I consent
By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.